ASH 2021 | Next-Generation BTK inhibitors and their role in the CLL treatment landscape
Barbara Eichhorst
• 16 Dec 2021
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses updates in treatment options for patients with CLL, drawing focus on Bruton’s tyrosine kinase (BTK) inhibitors and (B-cell lymphoma 2) BCL-2 inhibitors. Dr Eichhorst briefly discusses these treatment options, including patient prognosis and rates of progression-free survival (PFS). Following this, Dr Eichhorst mentions the promising data found on next-generation BTK inhibitors, such as pirtobrutinib, and their potential role in the future treatment of more aggressive CLL clones. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.
